⬅️️Click Here for Menu

Management

Dr. Brian Salmons is CEO, President and a Founder. He has had 20 years experience in biotech, starting as the Scientific Director of Bavarian Nordic. He co-founded Austrianova Biotechnology GmbH in 2001 and Austrianova in 2007. He was directly responsible for the initial Phase I/II clinical trials of an encapsulated cell product in pancreatic cancer in humans and mammary (breast) cancer in dogs and was part of the team that took Bavarian Nordic to its IPO in 1998.
Dr. Brian Salmons is CEO, President and a Founder. He has had 20 years experience in biotech, starting as the Scientific Director of Bavarian Nordic. He co-founded Austrianova Biotechnology GmbH in 2001 and Austrianova in 2007. He was directly responsible for the initial Phase I/II clinical trials of an encapsulated cell product in pancreatic cancer in humans and mammary (breast) cancer in dogs and was part of the team that took Bavarian Nordic to its IPO in 1998.
Prof. Walter H. Günzburg, Ph.D. is the Chairman and a founder. He is also the Professor of Virology at the University of Veterinary Medicine, Vienna, Austria and formerly an Adjunct Professor at the National University of Singapore and director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development in Vienna. He has also served as a member of German Federal Medical Association Ethics Committee for Gene Therapy.
Prof. Walter H. Günzburg, Ph.D. is the Chairman and a founder. He is also the Professor of Virology at the University of Veterinary Medicine, Vienna, Austria and formerly an Adjunct Professor at the National University of Singapore and director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development in Vienna. He has also served as a member of German Federal Medical Association Ethics Committee for Gene Therapy.
Dr John Dangerfield was appointed Chief Operating Officer of SG Austria in 2010, having previously been Head of Laboratory (2007-2010). He has previous experience in quality control for pharmaceuticals at Amersham Pharmacia Biotech in UK. In the past years he has co-authored 11 publications and book chapters and has been involved in procuring 9 industrial and research grants. He also has co-edited an e-book on encapsulation.
Dr John Dangerfield was appointed Chief Operating Officer of SG Austria in 2010, having previously been Head of Laboratory (2007-2010).
He has previous experience in quality control for pharmaceuticals at Amersham Pharmacia Biotech in UK.
In the past years he has co-authored 11 publications and book chapters and has been involved in procuring 9 industrial and research grants. He also has co-edited an e-book on encapsulation.